

Virus detail

hCoV-19/England/LOND-1293FC4/2022 Virus name:

Accession ID: EPI ISL 13090312.1 Type: betacoronavirus

Clade:

Pango Lineage: BA.2.9 (Pango v.4.0.6 PLEARN-v1.8), Omicron (BA.2-like) (Scorpio)

Spike A27S, Spike D405N, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike H655Y, Spike **AA Substitutions:**

K417N, Spike L24del, Spike N440K, Spike N501Y, Spike N679K, Spike N764K, Spike N969K, Spike P25del, Spike P26del, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike R408S, Spike S477N, Spike T19I, Spike T478K, Spike V213G, Spike Y505H, E T9I, M A63T, M Q19E, N E31del, N G204R, N P13L, N R32del, N R203K, N S33del, N S413R, NS3 H78Y, NS3 T223I, NSP1 S135R, NSP3 G489S, NSP3 T24I, NSP4 L264F, NSP4 L438F, NSP4 T327I, NSP4 T492I, NSP5 P132H, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12

Stretches of NNNs (1.67% of overall sequence). Gap of 53 nucleotides when compared to the reference WIV04

P323L, NSP13 R392C, NSP14 I42V, NSP15 T112I

Variant: VOC Omicron GRA (B.1.1.529+BA.*) first detected in Botswana/Hong Kong/South Africa

Passage details/history:

Sample information

Collection date: 2022-04-11

Location: Europe / United Kingdom / England

Host: Human

Additional location information:

Gender: unknown Patient age: unknown Patient status: unknown

Specimen source:

Additional host information:

Sampling strategy:

Outbreak:

Last vaccinated: Treatment:

Sequencing technology:

Illumina

Assembly method:

Coverage: Comment:

sequence

Institute information

Barts Health NHS Trust Originating lab:

Address: London

Sample ID given by the

originating laboratory:

LOND-1293FC4

COVID-19 Genomics UK (COG-UK) Consortium **Submitting lab:**

Address: United Kingdom Sample ID given by the LOND-1293FC4

submitting laboratory:

CUTINO-MOGUEL, Maria-Teresa; HARRINGTON, David; HARRIS, Kathryn; SULTANA, Shahiba; KELE, Authors:

Beatrix

Submitter information

Kele, Beatrix Submitter: **Submission Date:** 2022-06-03

Address:

Important note: In the GISAID EpiFluTM Database Access Agreement, you have accepted certain terms and conditions for viewing and using data regarding influenza viruses. To the extent the Database contains data relating to non-influenza viruses, the viewing and use of these data is subject to the same terms and conditions, and by viewing or using such data you agree to be bound by the terms of the GISAID EpiFluTM Database Access Agreement in respect of such data in the same manner as if they were data relating to influenza viruses.